SR One Capital Management portfolio
Private equity or venture capitalPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 12, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
SR One Capital Management reported a $1.0 bn portfolio of 15 positions to the SEC as of the end of Q2 2026. Its largest positions are MANE, ZBIO, CRSP. During the quarter it exited Oruka Therapeutics.
Sections with a free account
What changed this quarter
2 positions with a change (1 added to, 1 sold); also, 2 entered through an IPO, 1 exited through an acquisition or merger, 1 entered through a spin-off. 1 is listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedAvalyn PharmaAVLN10.5% of the portfolio
- Newly listedMobia MedicalMOBI2.6% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Oruka Therapeutics−2.0 ppof portfolioSold out2.3% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- VeradermicsMANE28.4%
- Zenas BioPharmaZBIO12.3%
- Crispr TherapeuticsCRSP10.7%
- Avalyn PharmaAVLN10.5%
- Design TherapeuticsDSGN9.1%
- Odyssey TherapeuticsODTX6.8%
- AlumisALMS5.3%
- ORIC PharmaceuticalsORIC4.8%
- Mineralys TherapeuticsMLYS4.1%
- ARS PharmaceuticalsSPRY3.1%
- Mobia MedicalMOBI2.6%
- NkartaNKTX0.9%
- Oculis HoldingOCS0.9%
- Ultragenyx PharmaceuticalRARE0.4%
- enGene Therapeutics0.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 15
Q2 2026: 95%
Q2 2026: 7.6%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Private equity or venture capital, per its Form ADV of Mar 31, 2026 (high confidence).
The data, as reported: SR ONE CAPITAL MANAGEMENT, LP (CRD 306361): 7.B private funds: 19 pe (gross assets $2.4 bn); 5.D assets by client type: pooled vehicles 100% (of $2.4 bn) · 13F: 63% of the portfolio was already held when the stock started trading
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: it is a private equity or venture firm; its stocks are usually holdings that went public. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Wolf Hill Capital ManagementInvestment firm · $1.0 bn
- Engine Capital ManagementInvestment firm · $1.0 bn
- Apis Capital AdvisorsInvestment firm · $1.0 bn
- Melqart Asset Management (UK)Investment firm · $1.1 bn
- Fort Baker Capital ManagementInvestment firm · $1.0 bn
- Minneapolis Portfolio Management Group$1.1 bn